Randomized Trialhigh evidence
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.
Nature medicine·April 1, 2026·PMID 41629425
Why it mattersTiming of immunotherapy infusion is a low-cost, easily implementable factor that may substantially enhance outcomes in NSCLC. This prospective evidence supports considering time-of-day scheduling to optimize treatment efficacy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled